Nikki Kit
Product Images NDC 68180-886

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Nikki (NDC 68180-886). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (A30b8aed 1e92 49b7 9d4b 47adf6cec7c2 01)

A forest plot displaying hazard ratios, rate ratios, and odds ratios for various studies including Ingenix, EURAS, LASS, FDA-funded, Danish, MEGA, German case-control, PharMetrics, and GPRD. The studies are grouped into prospective cohort, retrospective cohort, case-control, and non-fetal idiopathic cases categories, with a horizontal axis ranging from 0.1 to 10 and markers indicating effect estimates and confidence intervals.*

FDA Label Image

Fig-2 (A30b8aed 1e92 49b7 9d4b 47adf6cec7c2 02)

A horizontal bar chart comparing the number of women with a blood clot per 10,000 women years (WY) among four groups: Non-Pregnant Non-COC users (range 1 to 5), COC-Users (range 3 to 9), Pregnant women (range 5 to 20), and Postpartum women (12 weeks only, range 40 to 65). An asterisk notes pregnancy data is based on actual duration of pregnancy with a model assumption of nine months.*

FDA Label Image

1 (A30b8aed 1e92 49b7 9d4b 47adf6cec7c2 03)

A forest plot chart showing effect estimates with confidence intervals for several studies comparing contraceptive use categories: Ever COC use vs. Never COC use, and Current COC use vs. Never use. Studies listed include NICHD Women’s Care Study 2002, French E3N cohort 2005, Shanghai Women’s Health Study 2009, Nurses' Health Study II 2010, Oxford Family Planning Study 2013, and Danish Sex Hormone Register Study 2017. Effect estimates like odds ratios (OR), risk ratios (RR), and hazard ratios (HR) are plotted along a horizontal axis labeled 'Effect Estimate.'*

FDA Label Image

Fig-3 (A30b8aed 1e92 49b7 9d4b 47adf6cec7c2 04)

Chemical structure of Drospirenone and Ethinyl estradiol shown side by side, depicting the molecular frameworks of these two active ingredients.*

FDA Label Image

Fig-4 (A30b8aed 1e92 49b7 9d4b 47adf6cec7c2 05)

A vertical arrow chart showing pregnancy rates per 100 women in one year and various birth control methods. It ranks methods from 'Fewer Pregnancies' at the top (implants, injections, intrauterine devices, sterilization) to 'More Pregnancies' at the bottom (no birth control), with other methods like birth control pills, patches, rings, condoms, diaphragms, abstinence during fertile days, spermicide, and withdrawal placed accordingly.*

FDA Label Image

Fig-5 (A30b8aed 1e92 49b7 9d4b 47adf6cec7c2 06)

An illustrated monthly pill card for Nikki (drospirenone and ethinyl estradiol tablets USP) 3 mg/0.02 mg, showing a 28-day sequence divided into four rows labeled Week 1 to Week 4, with each day of the week (Sunday to Saturday) marked by empty circles indicating pill placement. Arrows guide order of use, starting from Sunday Week 1 through Saturday Week 4, accompanied by instructions to start on the first Sunday. Additional text advises storing at 25°C (77°F) with allowed excursions to 15–30°C (59–86°F). The panel includes a reminder for monthly self-breast exams and the Lupin Pharmaceuticals logo.*

FDA Label Image

Fig-6 (A30b8aed 1e92 49b7 9d4b 47adf6cec7c2 07)

A horizontal bar chart showing the number of women with a blood clot per 10,000 women years (WY) across four groups: Non-Pregnant Non-COC users (1 to 5), COC users (3 to 9), Pregnancy (5 to 20), and Postpartum (12 weeks only) with the highest range (40 to 65). The chart highlights increased blood clot rates in postpartum and pregnancy groups compared to others.*

FDA Label Image

Fig-7 (A30b8aed 1e92 49b7 9d4b 47adf6cec7c2 08)

The image shows the lidding foil and forming foil/PVC side of Nikki (drospirenone and ethinyl estradiol tablets USP) with a strength of 3 mg/0.02 mg. The lidding foil side includes storage instructions, manufacturer Lupin Limited (India), distributor Lupin Pharmaceuticals, Inc. (Baltimore, Maryland), NDC 68180-886-71, and lot/expiration placeholders. The forming foil side displays a 4-week calendar layout with circles for each day and an indication for monthly self-breast exams.*

FDA Label Image

Pouch (A30b8aed 1e92 49b7 9d4b 47adf6cec7c2 09)

Packaging label for Nikki tablets by Lupin Pharmaceuticals, Inc. The label shows Nikki containing drospirenone and ethinyl estradiol USP with a strength of 3 mg/0.02 mg. It is labeled as 1 blister of 28 tablets with NDC 68180-886-71. Additional text includes storage instructions, prescription information, and distributor details.*

FDA Label Image

Carton (A30b8aed 1e92 49b7 9d4b 47adf6cec7c2 10)

Packaging label for Nikki tablets containing drospirenone and ethinyl estradiol USP at 3 mg/0.02 mg strength. The label indicates 3 blisters of 28 tablets each, distributed by Lupin Pharmaceuticals, Inc. The design includes product name, active ingredients, dosage strength, Rx only status, and barcodes. Manufacturer listed as Lupin Limited, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.